RMD

Business profile & competitive position

ResMed Inc. is classified in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. Its core business is digital health and cloud-connected medical devices for sleep and breathing health, including CPAP, APAP, bilevel, and ventilation devices, masks, diagnostics, dental devices, and connected-care software. The company also sells cloud-based Residential Care Software to home medical equipment, home health, hospice, skilled nursing, and senior living providers, and it distributes products in more than 140 countries through subsidiaries and independent distributors.

The financial profile indicates real competitive strengths. ResMed’s net margin is 26.9% and its return on equity is 23.9%. Those figures sit well above what is typical for commodity medical-supply companies, suggesting meaningful pricing power, recurring revenue from masks and software, and durable customer relationships tied to AirView remote monitoring and the myAir patient engagement platform. The company reports more than 35 million cloud-connected devices on AirView and over 12 million patients registered on myAir, which reinforces a recurring ecosystem around device purchases and replacement masks.

Revenue in fiscal 2026 was roughly balanced across devices at ~51% of net revenue, masks/diagnostics/accessories at ~37%, and software at ~12%. That split points to a business that is not only selling devices, but also capturing ongoing demand for disposables and digital services.

Financial posture

ResMed carries a market capitalization of $35.6 billion and trades at a trailing P/E ratio of 24.3. That valuation is lower than many high-growth-medical-tech peers in absolute terms, yet still implies a premium-execution requirement: the company must keep converting its installed base into recurring revenue and hold margins near current levels for the multiple to be justified.

The profitability profile is strong. Net margin is 26.9%, ROE is 23.9%, and the stock’s beta is 0.75, meaning it has historically moved less violently than the broad market. At the current price of $253.20, the stock is comfortably above its 50-day exponential moving average of $229.71, and the relative strength index is 77.4, which reads as technically extended. None of these figures by themselves predict direction, but together they portray a large, profitable, low-volatility healthcare franchise that is currently priced for continued steady execution.

Strategic priorities & outlook

ResMed’s most recent 10-K filing outlines four near-term operational priorities. First, it aims to grow and differentiate the core sleep apnea portfolio by integrating artificial intelligence and machine learning, simplifying care pathways, and expanding home diagnostics such as NightOwl and the VirtuOx IDTF acquisition. Second, management wants to accelerate market growth by building awareness and education among patients, physicians, and special-interest groups around sleep apnea, COPD, and related comorbidities. Third, the company is targeting broader sleep and breathing health adjacencies, including COPD, neuromuscular disease, and restless legs syndrome, supported by the Noctrix acquisition. Fourth, it plans to invest in an integrated, intelligent digital-health ecosystem delivered at home, anchored by AirView remote monitoring and the myAir patient engagement platform.

A notable strategic move is the planned sale of the MatrixCare business. In June 2026 ResMed agreed to sell MatrixCare for $490 million in cash, with the transaction expected to close in the first quarter of fiscal 2027. The rationale is to sharpen focus on core sleep, breathing, and connected home-based healthcare rather than maintaining a broader but less aligned software footprint.

Macro & geopolitical exposure

Because ResMed sits in the Healthcare / Medical - Instruments & Supplies industry, its macro exposure is relatively defensive but not immune to sector-specific risks. The company is exposed to healthcare reimbursement policy and regulatory approvals for its devices across the United States, Europe, Asia-Pacific, and more than 140 other markets. Changes in Medicare or private-insurer coverage for sleep apnea diagnostics and CPAP therapy can alter demand and pricing power.

Trade policy is another relevant factor. Devices and components manufactured in one region and sold globally can be affected by tariffs, freight costs, and supply-chain disruptions. Currency movements also matter because roughly half of the business is international; a stronger U.S. dollar can dampen translated overseas revenue. Finally, the company is exposed to semiconductor and sensor supply markets given the cloud-connectivity hardware inside its devices, although its scale and long-term distributor relationships tend to mitigate near-term input volatility.

Recent developments

The recent press flow has centered on ResMed’s upcoming fiscal first-quarter report. On October 26, 2026, Zacks published “Why Investors Need to Take Advantage of These 2 Medical Stocks Now.” On October 23, 2026, Zacks ran both “Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?” and “ResMed Set to Report Q1 Earnings: What’s in the Cards for the Stock?” A day earlier, on October 22, 2026, Zacks published “ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week’s Release.” These headlines collectively frame the market’s focus on whether ResMed can extend its string of earnings beats when it reports after the close on October 29, 2026.

The current consensus EPS estimate for that report is $2.69. Traders should note that the stock’s RSI is already at 77.4 and the price sits $23.49 above its 50-day EMA, conditions that can amplify volatility around the headline number.

Earnings behavior & post-earnings drift

ResMed has beaten analyst estimates in 7 of the last 8 reported quarters, for an 88% beat rate, with an average earnings surprise of 3%. That track record indicates the company reliably clears the market’s real expectation, though not by a wide margin.

What is more interesting is the market’s reaction function. The average 5-day price move in the five trading days after earnings across the last eight quarters is just 0.24%, classified as flat. In the four most recent reports, this flat drift masks real chop. The August 6, 2026 report delivered EPS of $2.95 versus an estimate of $2.89, a 2.1% beat, yet the stock fell 5.06% the next day and rose only 1.57% over the next five days. On April 30, 2026, EPS of $2.86 beat the $2.80 estimate by 2.1%, but the stock dropped 4.11% the next session and fell 3.24% over the following five days. On January 29, 2026, EPS of $2.81 beat the $2.74 estimate by 2.6%, producing a modest 0.27% next-day gain and a healthier 3.66% five-day move. The October 30, 2025 report saw EPS of $2.55 against a $2.51 estimate, a 1.6% beat, with the stock down 2.13% the next day and down 1.03% over the next five days.

The takeaway from this data is that meeting or beating EPS estimates has not reliably produced upward drift in ResMed shares; in three of the last four quarters the next-day move was negative despite the beat. The 3% average surprise appears to be priced in, and the post-earnings path may depend more on guidance, margin commentary, and how the market is positioned heading into the release.

For a deeper dive into the institutional consensus, detailed valuation scenarios, and the latest analyst revisions ahead of the October 29 report, readers should review the full institutional verdict rather than relying solely on the headline numbers above.